PGEN
NASDAQ · Biotechnology
Precigen Inc
$3.19
+0.06 (+1.92%)
Open$3.13
Previous Close$3.13
Day High$3.20
Day Low$3.09
52W High$5.47
52W Low$1.11
Volume—
Avg Volume2.59M
Market Cap1.17B
P/E Ratio—
EPS$-0.82
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+2,174.9% upside
Current
$3.19
$3.19
Target
$72.57
$72.57
$43.64
$72.57 avg
$99.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.26M | 8.10M | 411.38M |
| Net Income | -168,862,736 | -233,845,918 | -34,816,902 |
| Profit Margin | -3,216.2% | -3,055.4% | -8.5% |
| EBITDA | -167,107,853 | -244,272,134 | -49,679,638 |
| Free Cash Flow | — | — | -21,385,787 |
| Rev Growth | -35.0% | -35.0% | +17.8% |
| Debt/Equity | — | — | 0.95 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |